|
- NCCN Recommends Only One Genomic Test for Breast Cancer
HOLLYWOOD, Florida — The National Comprehensive Cancer Network (NCCN) only endorses one genomic test for use in patients with early-stage breast cancer, according to a presenter here at the NCCN
- NCCN Expands Cancer Genetic Risk Assessment Guidelines
Updates to two genetic risk assessment guidelines now include prostate, endometrial, and gastric cancer to reflect the growing understanding of hereditary cancer risk and value of genetic testing
- New NCCN Guidelines for Mammography: All Women Over 40 - Medscape
New evidence-based and patient-facing guidelines aim to simplify the message — and call for annual mammography for average-risk women older than 40
- Adult Cancer Pain: Part 2 -- The Latest Guidelines for Pain Management
Editor's note This is the second in a 2-part article describing the changes to the National Comprehensive Cancer Network's (NCCN) updated 2010 guidelines on the management of adult cancer pain
- Breast Cancer Guidelines Compared: ESMO vs NCCN - Medscape
A comparison of breast cancer guidelines from two of the world's most prominent oncology organizations, the National Comprehensive Cancer Network (NCCN) and the European Society of Medical
- NCCN Guidelines Embrace PSMA-PET Imaging for Prostate Cancer - Medscape
The footnote in the new NCCN guidelines states that "because of the increased sensitivity and specificity of PSMA-PET tracers for detecting micrometastatic disease compared to conventional imaging
- New ASCO Guidelines for Advanced Ovarian Cancer - Medscape
Based on the NCCN guidelines, treatment selection for ovarian cancer is primarily determined by the histologic subtype, stage of disease, and whether the patient is a candidate for primary surgery
- Cancer Drug Shortages Continue in the US, Survey Finds
The NCCN also continues to work with federal regulators, agencies, and lawmakers to implement long-term solutions to cancer drug shortages
|
|
|